SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-273808
Filing Date
2023-11-09
Accepted
2023-11-08 21:16:51
Documents
13
Period of Report
2023-11-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d139069d8k.htm   iXBRL 8-K 25645
2 EX-99.1 d139069dex991.htm EX-99.1 14066
  Complete submission text file 0001193125-23-273808.txt   166917

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20231108.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20231108_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20231108_pre.xml EX-101.PRE 11263
7 EXTRACTED XBRL INSTANCE DOCUMENT d139069d8k_htm.xml XML 3370
Mailing Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320
Business Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 805-623-4244
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 231389754
SIC: 2836 Biological Products, (No Diagnostic Substances)